Skip to content
Study details
Enrolling now

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136)

Eli Lilly and Company
NCT IDNCT07215559ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

200

Study length

about 1.6 years

Ages

18–75

Locations

22 sites in AZ, GA, NJ +5

Why this study is shown

Actively enrollingPHASE2

What this study is about

Researchers are testing macupatide and eloralintide, alone or in combination, to see if they help people with obesity or overweight who also have type 2 diabetes lose weight. The trial will last about 48 weeks.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Eloralintide
  • 2.Take Eloralintide Placebo
  • 3.Take Macupatide
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Percent Change from Baseline in Body Weight

Secondary: Change from Baseline in Body Mass Index (BMI), Change from Baseline in Fasting Glucose, Change from Baseline in Hemoglobin A1c (HbA1c)

Body systems

Endocrinology